Lucid Diagnostics Inc.

LUCD · Nasdaq · SIC 3841: Surgical & Medical Instruments & Apparatus · Market Cap: $0.2B · 82 employees
108
SEC Filings
$1.03
Close 2026-06-01
82
Employees

Business Summary

Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company focused on detecting esophageal precancer and cancer in patients with gastroesophageal reflux disease (GERD). Its flagship product, the EsoGuard Esophageal DNA Test, is performed on samples collected with the EsoCheck Esophageal Cell Collection Device. EsoGuard is a bisulfite-converted targeted next-generation sequencing DNA assay quantifying methylation at 31 sites on VIM and CCNA1 genes. The company operates Lucid Test Centers, satellite test center programs, and mobile testing units across the U.S.

Latest Stock Quote

LUCD 2026-06-01 $1.03 O:$1.03 H:$1.05 L:$1 Vol:0.9M VWAP:$1.0334
origin leaf: 958f007c03b65165038c351bccecfb364a36728be133e61e838995aeea7046d1

Next Earnings

Q2 FY2026 — expected 2026-09-14

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-252025-12-310001437749-26-009805EDGAR73K words
2025-03-242024-12-310001641172-25-000205EDGAR
2024-03-252023-12-310001493152-24-011161EDGAR
2023-03-142022-12-310001493152-23-007482EDGAR
2022-04-062021-12-310001493152-22-009199EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001493152-25-021737EDGAR23K words
2025-08-122025-06-300001493152-25-011862EDGAR
2025-05-132025-03-310001641172-25-009986EDGAR
2024-11-122024-09-300001493152-24-044799EDGAR
2024-08-122024-06-300001493152-24-031168EDGAR
2024-05-132024-03-310001493152-24-018800EDGAR
2023-11-132023-09-300001493152-23-040623EDGAR
2023-08-142023-06-300001493152-23-028577EDGAR
2023-05-152023-03-310001493152-23-017413EDGAR
2022-11-142022-09-300001493152-22-032029EDGAR
2022-08-152022-06-300001493152-22-023043EDGAR
2022-05-162022-03-310001493152-22-013957EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-260001493152-26-012807EDGAR3K words
2025-11-120001493152-25-021748EDGAR
2025-09-250001493152-25-014872EDGAR
2025-09-110001493152-25-013046EDGAR
2025-09-100001493152-25-012962EDGAR
2025-08-130001493152-25-011882EDGAR
2025-06-180001641172-25-015613EDGAR
2025-05-300001641172-25-013059EDGAR
2025-05-140001641172-25-010101EDGAR
2025-04-250001641172-25-006239EDGAR

108 total filings indexed. 81 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

MMM — 3M CO ARAY — ACCURAY INC AEMD — AETHLON MEDICAL INC ALUR — ALLURION TECHNOLOGIES, INC. ANGO — ANGIODYNAMICS INC AORT — ARTIVION, INC. RCEL — AVITA Medical, Inc. ADGM — Adagio Medical Holdings, Inc.

Tags

esophageal-cancer-diagnostics gastroesophageal-reflux-disease-(gerd)-screening cancer-prevention-diagnostics primary-care-and-gastroenterology-physician-market fda-510(k)-clearance ce-mark-certification clia-certified-laboratory next-generation-sequencing-(ngs) bisulfite-conversion-dna-assay

Company Identity

CIK0001799011
TickerLUCD
ExchangeNasdaq
SIC3841: Surgical & Medical Instruments & Apparatus
IncorporatedDE
Websitehttps://www.luciddx.com
Listed2021-10-14

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: b4f40f545e80c96c0f1ad6683527de0f0239e914dbb20b560c623ef926d6a5cf
parent: f2db554c1c8b552746a4f410c97389408030ab95292852d714871c3b9c6b0e3a
content hash: a87ce619dd4cd39030d5b8e00bad52cd8fb0068eb7b5a1b4536ad622e348a700
signed: 2026-06-02T19:01:47.459Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf